Bortezomib API (CAS No: 179324-69-7): Complete Pharmaceutical Guide for Manufacturers, Suppliers, and Global Buyers
Introduction to Bortezomib API
Bortezomib API (CAS No: 179324-69-7) is a highly specialized anticancer active pharmaceutical ingredient widely used in oncology formulations, particularly for treating multiple myeloma and mantle cell lymphoma. If you are part of the pharmaceutical manufacturing or sourcing ecosystem, you already know how critical it is to work with APIs that deliver both clinical effectiveness and regulatory compliance. That’s exactly where Bortezomib stands out.
 |
| Bortezomib-API-CAS-No-179324-69-7-Complete-Pharmaceutical-Guide-for-Manufacturers-Suppliers-and-Global-Buyers |
This compound belongs to the class of proteasome inhibitors, a revolutionary category in cancer treatment that has significantly improved patient outcomes over the past two decades. Its role in disrupting cancer cell growth mechanisms has made it one of the most high-demand oncology APIs globally. Pharmaceutical companies across the world are actively seeking reliable Bortezomib API manufacturers and suppliers in India, especially those who can provide consistent quality and complete documentation.
The global oncology drug market continues to grow rapidly, driven by rising cancer incidence and increasing demand for targeted therapies. Within this space, Bortezomib plays a vital role due to its proven efficacy and well-established clinical use. As a result, the demand for bulk Bortezomib API supply is increasing, especially in regulated and semi-regulated markets.
From a sourcing perspective, choosing the right API supplier is not just about pricing—it’s about quality assurance, regulatory support, and long-term reliability. This guide will walk you through everything you need to know about Bortezomib API, from its chemical properties to market trends and supplier selection.
Chemical Profile and Properties
Understanding the chemical profile of Bortezomib API is essential for pharmaceutical manufacturers who aim to develop high-quality formulations. Bortezomib has a complex molecular structure designed specifically to target and inhibit proteasome activity in cancer cells. Its molecular formula is C19H25BN4O4, and it is typically available as a white to off-white powder.
The compound exhibits unique physicochemical properties that make it suitable for injectable formulations. It is moderately soluble in aqueous solutions and shows stability under controlled conditions. These characteristics are critical for ensuring the drug’s bioavailability and therapeutic effectiveness.
In pharmaceutical production, maintaining the integrity of these properties is crucial. Even slight variations in purity or composition can significantly impact the final product’s performance. That’s why leading Bortezomib API manufacturers in India follow stringent quality control protocols, including advanced analytical techniques like HPLC and IR spectroscopy.
Here’s a quick overview of key specifications:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white powder |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.2% |
| Heavy Metals | NMT 10 ppm |
These specifications ensure that the API meets IP/BP/USP/EP standards, making it suitable for global pharmaceutical applications.
Mechanism of Action
So, how does Bortezomib actually work? This is where things get fascinating. Bortezomib functions as a proteasome inhibitor, meaning it blocks the activity of proteasomes—cellular complexes responsible for breaking down proteins.
In cancer cells, proteasomes play a crucial role in regulating cell growth and survival. By inhibiting these structures, Bortezomib disrupts the degradation of pro-apoptotic factors, leading to the accumulation of defective proteins. This ultimately triggers cell death (apoptosis) in cancer cells.
Think of it like shutting down a waste disposal system in a factory. When waste accumulates beyond a certain point, the entire system collapses. That’s essentially what happens inside cancer cells when treated with Bortezomib.
This targeted mechanism is what makes Bortezomib highly effective in treating cancers like multiple myeloma, where abnormal plasma cells proliferate uncontrollably. Unlike traditional chemotherapy, which affects both healthy and cancerous cells, Bortezomib offers a more focused therapeutic approach.
Its effectiveness has been validated through numerous clinical studies, making it a cornerstone in modern oncology treatments. As a result, pharmaceutical companies are increasingly investing in high-quality Bortezomib API sourcing to meet growing market demand.
Therapeutic Applications
The primary use of Bortezomib API lies in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells. This condition is particularly challenging to treat, and Bortezomib has significantly improved survival rates when used as part of combination therapy.
In addition to multiple myeloma, Bortezomib is also used in the treatment of mantle cell lymphoma, another rare but aggressive form of cancer. Its ability to induce apoptosis in malignant cells makes it a valuable component in oncology drug formulations.
Pharmaceutical companies developing injectable formulations rely heavily on bulk Bortezomib API suppliers who can ensure consistent quality and regulatory compliance. The increasing prevalence of cancer worldwide has further fueled demand for this API.
According to global health data, cancer cases are expected to rise significantly over the next decade, driving the need for effective treatments. This trend directly impacts the demand for oncology APIs like Bortezomib.
As healthcare systems continue to evolve, the focus is shifting toward targeted therapies and personalized medicine, where Bortezomib plays a key role. This makes it an essential API for pharmaceutical manufacturers aiming to stay competitive in the oncology segment.
Manufacturing Process Overview
Producing Bortezomib API is a highly specialized process that requires advanced chemical synthesis techniques and strict adherence to quality standards. The manufacturing process involves multiple stages, including synthesis, purification, and final formulation.
Each stage must be carefully monitored to ensure the API meets required specifications. Leading Bortezomib API manufacturers in India invest heavily in state-of-the-art facilities and skilled personnel to maintain consistency and quality.
Quality control is a critical component of the manufacturing process. Analytical methods such as HPLC, GC, and IR spectroscopy are used to verify purity, identity, and stability. These tests ensure that the API is suitable for pharmaceutical use.
In addition to quality control, documentation plays a vital role. Reputable suppliers provide comprehensive documentation, including COA, DMF, MSDS, and stability data, which are essential for regulatory approvals.
Manufacturers must also comply with international standards such as WHO-GMP and USFDA guidelines, ensuring that their products can be exported to global markets.
Regulatory Compliance and Certifications
In the pharmaceutical industry, compliance is everything. When sourcing Bortezomib API, regulatory documentation is just as important as the product itself. Leading suppliers provide complete documentation packages to support global regulatory submissions.
Key certifications include:
- WHO-GMP compliance
- DMF (Drug Master File) support
- ISO certification
- ICH guidelines adherence
These certifications ensure that the API meets international quality standards and can be used in regulated markets like the US, Europe, and Japan.
Market Demand and Growth Trends
The demand for Bortezomib API is closely linked to the growth of the global oncology market. With cancer cases rising worldwide, the need for effective treatments continues to increase.
India has emerged as a leading hub for API manufacturing and export, offering cost-effective solutions without compromising on quality. This makes Indian suppliers highly attractive to global pharmaceutical companies.
The oncology API segment is expected to grow at a significant rate, driven by advancements in drug development and increasing healthcare investments.
Packaging, Storage, and Stability
Proper storage and packaging are essential to maintain the stability of Bortezomib API. The product should be stored in a cool, dry place, away from direct sunlight and moisture.
High-quality packaging, such as HDPE drums with inner liners, ensures product integrity during transportation and storage. Stability studies are conducted to determine shelf life and optimal storage conditions.
Choosing a Reliable Bortezomib API Supplier
Selecting the right supplier is crucial for ensuring product quality and regulatory compliance. Key factors to consider include:
- Manufacturing capabilities
- Quality certifications
- Documentation support
- Global export experience
A reliable supplier will offer consistent quality, competitive pricing, and timely delivery.
Company Overview – Swapnroop Drugs and Pharmaceuticals
Swapnroop Drugs and Pharmaceuticals is a trusted name in the pharmaceutical industry, specializing in the manufacturing and supply of high-quality APIs, excipients, and pellets. With a strong commitment to quality and compliance, the company provides DMF-grade materials with complete regulatory documentation.
The company serves global markets with a focus on WHO-GMP standards, batch consistency, and on-time delivery. Their expertise in bulk API supply makes them a preferred partner for pharmaceutical manufacturers worldwide.
Conclusion
Bortezomib API is a critical component in modern oncology treatments, offering targeted therapeutic benefits and strong clinical performance. With increasing global demand, sourcing from a reliable manufacturer is more important than ever.
FAQs
1. What is Bortezomib API used for?
Bortezomib API is primarily used in the treatment of multiple myeloma and mantle cell lymphoma.
2. What is the CAS number of Bortezomib?
The CAS number of Bortezomib is 179324-69-7.
3. Is Bortezomib API available in bulk supply?
Yes, it is available from bulk manufacturers and suppliers in India.
4. What certifications should a Bortezomib supplier have?
WHO-GMP, DMF support, and ISO certifications are essential.
5. How should Bortezomib API be stored?
It should be stored in a cool, dry place away from sunlight.
6. What does Swapnroop Drugs and Pharmaceuticals offer?
They provide high-quality APIs with full regulatory support and global export capabilities.
Bortezomib API Manufacturer Supplier in India (City Coverage)
We are a trusted Bortezomib API manufacturer supplier in India, offering high-quality products with reliable bulk supply, consistent quality, and timely delivery across major industrial and pharmaceutical hubs.
Comments
Post a Comment